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Abstract 
New stability indicating chromatographic methods have been developed for 
estimation of Assay and Impurities of Docetaxel in Docetaxel injection for 
evaluation of pharmaceutical quality. With this method, the process related 
impurities and degradants are well separated from the peaks due to placebo. 
The relative retention times and relative response factors of the known 
impurities have been established. The LOQ of the known impurities and 
docetaxel are found to be less than 0.2 μg /ml and the recovery falls in the 
range of 90–110%. Peak purities demonstrated the stability indicating nature of 
the methods. The methods developed in the present study overcome the 
lacunae of the existing published methodologies in evaluation of the quality of 
Docetaxel injection. In essence, the present study provides an improved 
methodology for evaluation of the pharmaceutical quality of Docetaxel injection.  
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Introduction 
Docetaxel is an antineoplastic agent and belongs to the taxoid family. Docetaxel is of the 
chemotherapy drug class of taxanes and is a semi-synthetic analogue of paclitaxel, an 
extract from the rare Pacific yew tree Taxus brevifolia. Due to scarcity of paclitaxel, 
extensive research was carried out leading to the discovery of docetaxel – an esterified 
product of 10-deacetyl baccatin III, which is extracted from the renewable and readily 
available  European yew tree. Docetaxel differs from Paclitaxel at two positions in its 
chemical structure (Figure 1). It has a hydroxyl functional group on carbon 10, whereas 
paclitaxel has an acetate ester and a tert-butyl substitution exists on the phenyl propionate 
side chain. Docetaxel is a white powder. 
Docetaxel formulation is supplied as injection concentrate as 20 mg and 80 mg single-
dose vials as a sterile, pyrogen-free, non-aqueous, viscous solution by Sanofi-Aventis 
under brand name of Taxotere
®. A sterile, non-pyrogenic, single-dose diluents (13% 
ethanol in water for injection) is supplied for dilution of the formulation [1, 2]. Docetere
TM is 
supplied as 20 mg and 80 mg single-dose vials as a sterile, pyrogen-free, non-aqueous, 
viscous solution by Dr. Reddy’s Laboratories Limited along with a sterile, non-pyrogenic, 
single-dose diluents (13% ethanol in water for injection) for dilution of the formulation. 
The evaluation of quality of a drug substance requires complete understanding on the 
chemistry of drug molecule, its potential process and degradation related impurities. 
Isolation and characterization of some process related impurities [3] and degradation 
impurities of docetaxel are also published [4]. A stability indicating HPLC assay method for 
Docetaxel has been reported [5]. A method for estimation of related substances of 
Docetaxel trihydrate drug substance is also published in Pharmeuropa [6]. The methods 
for the determination of Docetaxel in human plasma are available in literature [7–9].  
On the other hand, the evaluation of quality of a drug product requires complete 
understanding of the placebo matrix used for formulation and degradation of the drug in 
presence of the placebo during storage throughout its shelf life. Methods for determination 
of docetaxel and its related substances in docetaxel injection by HPLC are also reported 
[10, 11], but no details of degradants of docetaxel in the docetaxel formulation are given. 
Jerome et al [12] have made an attempt to determine the pharmaceutical quality of 
docetaxel formulations, by employing a method for limit of degradation products of 
paclitaxel injection given in United States Pharmacopeia (USP). 
In essence, the methods in the literature address impurities which are either process 
related or degradation related. There are no attempts made to separate and identify the 
drug related impurities in presence of formulation matrix. According to the current good 
manufacturing practices, all drug products must be tested with stability indicating methods 
wherein all the impurities are separated from placebo. Attempts are required to 
systematically understand appropriate and adequate methodologies of evaluation of 
quality of drug product of docetaxel injection. Hence the present study is aimed at 
developing a new stability indicating chromatographic method for estimation of docetaxel 
and its degradation products in docetaxel injection. The present work establishes 
methodology for the evaluation of docetaxel injection involving accurate identification and 
quantification Drug related impurities in Docetaxel injection by overcoming the lacunae 
existing in the published methodologies.   Evaluation of the Pharmaceutical Quality of Docetaxel Injection Using New Stability Indicating …  217 
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Fig. 1.  Structures of Docetaxel, Paclitaxel, Polysorbate 80 and Impurities of Docetaxel. 218  A. Malleswara Reddy et al.:  
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Results and Discussion 
Impurities 
Initially, attempts were made to understand the docetaxel formulation matrix before 
evaluation of the formulation's quality. Doecetaxel is practically insoluble in water and 
freely soluble in anhydrous ethanol and soluble in methylene chloride [6]. Due to its 
insoluble nature, polysorbate 80 is used as a solubilizer to formulate docetaxel as 
injection. The innovator product Taxotere
® is a formulation of docetaxel using polysorbate 
80 [1, 2]. Most generic formulations of docetaxel injection also contain polysorbate 80. 
Therefore, the present study focuses only on the estimation of impurities in docetaxel 
formulation with polysorbate 80 as matrix.  
The polysorbate 80 is a nonionic surfactant and emulsifier derived from polyethoxylated 
sorbitan and oleic acid, which comes from fruit and berries and is often used in foods. In 
the nomenclature of polysorbates, the numeric designation following polysorbate refers to 
the lipophilic group, in this case the oleic acid. Polysorbate 80 has been widely used as 
emulsifier and solubilizer in Pharmaceutical. Polysorbate 80 is official in NF (USP), 
Japanese Pharmacopoeia (JP) and European Pharmacopoeia (Ph. Eur.). The quality of 
the Polysorbate 80 is evaluated by the tests like specific gravity, viscosity, acid value, 
hydroxyl value, saponification value, water content, residue on ignition, heavy metals and 
organic volatile impurities apart from identification tests. 
Due to its chemical structure (Figure 1), polysorbate 80 gives peaks in chromatographic 
methods, depending on the detector that is employed. Hence, to evaluate any formulation 
that contains polysorbate 80 one needs to study the interference of the peaks due to 
polysorbate 80 for the estimation of drug related impurities. Therefore, the separation of 
drug related impurities from the peaks due to polysorbate 80 is essential in making the 
quality assessment of the docetaxel injection. Hence, the knowledge of degradation 
products of docetaxel plays a key role in evaluation of pharmaceutical quality of docetaxel 
injection. The structures of potential process related impurities of docetaxel trihydrate drug 
substance and the degradation products of docetaxel are listed in Figure 1.  
An adequate methodology for assessing the quality of docetaxel injection needs to 
address the separation of potential process related impurities & degradants from each 
other and from placebo peaks if any. Otherwise, the methods would suffer from the 
following disadvantages. (a) Lack of clarity regarding the peaks due to impurities and 
placebo would lead to possibility of estimation of placebo peaks as Impurities of docetaxel. 
(b) In cases where peaks due to impurities and placebo merge, the impurities peaks likely 
to get excluded as placebo, leading to possibility underestimation of impurities (c) In cases 
where the placebo components interfere with drug peak and impurity peaks will lead to 
possible overestimation. None of the publications available in open literature made any 
mention about efforts to specifically separate the degradation products from placebo 
components and assess the quality by its drug related impurities. Hence these methods 
are not adequate for estimation of drug related impurities in docetaxel injection.  
The recent publication [12] makes no mention of details to differentiate the drug related 
impurities from placebo peaks. On employing this method, it is found to be deficient for 
analysis of docetaxel formulation on the following two counts. Firstly, as a major degradant 
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1.14. The overlay chromatogram of placebo with impurities at 0.6% level is shown in 
Figure 2. Secondly, other placebo peaks at relative retention time of 0.88, 0.90 and 1.51 
are considered as impurities of docetaxel.  The following points are considered as 
mandatory in the present study to finalize the analytical method as suitable in evaluation of 
the quality of the formulation in addition to the method being stability indicating. (a) 
Determination of retention times of the drug related impurities authentically. (b) 
Establishment of relative response factors to facilitate accurate quantification of known 
impurities. (c) Verification of the sensitivity of the analytical method by establishing the 
LOQ of the drug and its known impurities. All the above points have not been addressed in 
the published methods, related to docetaxel formulation, known till date. 
In the present study, all the above requirements have been met leading to right 
methodology involving accurate identification and quantification drug related impurities in 
docetaxel formulations.  The new chromatographic method developed is found to be 
capable of separating the process impurities, degradation products of docetaxel from 
placebo. The overlay chromatogram of placebo, drug product as such and drug product 
spiked with impurities is shown in Figure 3. 
The authentic impurity standards are used for establishing their relative retention times. As 
standards of 7-epi-10-deacetylbaccatin III, 7-epi-10-oxo-10-deacetylbaccatin III are not 
available, the retention times are established based on forced degradation followed by LC-
MS study. The method has also been proved to be suitable for separation of drug related 
impurities from peaks of different grades of polysorbate 80 (Figure 4). However, as 
different docetaxel injection formulations can use different placebo components, it is 
appropriate to separate peaks due to placebo from the drug related impurities while 
evaluation of quality of docetaxel formulations.  
 
Fig. 2.   Overlay chromatogram of placebo with impurities blend (0.6%) in the literature 
method [12]. 
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Method development and optimization 
The HPLC method is optimized with a view to develop a stability indicating Assay and 
impurities methods. 7-epi Docetaxel, a major degradation product is found to be merging 
with placebo peak at relative retention time of 1.14 in the literature methods. The key 
objective of ‘chromatographic method’ is to get the separation of 7-epidocetaxel from 
placebo peak. Placebo and pure drug along with its related impurities are injected and run 
in different solvent systems. Our preliminary trials using different compositions of water, 
acetonitrile on different reversed phase stationary phases (ACE and X-Terra columns) did 
not give separation between pacebo peak and 7-epidocetaxel in a C-18 column. 
Introduction of another organic modifier methanol into the mobile phase resulted in moving 
the placebo peak away from impurities. Then the gradient program is optimized to elute 
the early eluting degradants like 10-DAB and to get the adequate separation of placebo 
peaks from all impurities in a C-18 Column.  
 
Fig. 3.   Overlay of chromatograms of Placebo (bottom), drug product (middle) and 
impurities spiked drug product (top). 
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Specificity and mass balance study 
No considerable degradation is observed in docetaxel drug product under stress 
conditions of photolytic stress. Stress study conditions and mass balance data are given in 
Table 1. Peak purity test results obtained from PDA confirm that the docetaxel peak is 
homogeneous and pure in all the analyzed stress samples. The mass balance data of 
stressed samples is greater than 96%, which confirms the stability indicating power of the 
method. The base stressed chromatogram and purity plot of docetaxel injection is shown 
in Figure 5. 
 
Fig. 4.   Overlay of chromatograms of impurities spiked drug product and different 
grades of polysorbate 80. 222  A. Malleswara Reddy et al.:  
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Relative response factors 
Relative response factors (RRF) are established for all the known impurities as the ratio of 
slope of impurities and slope of docetaxel. Slope value obtained with linearity calibration 
plot is used for RRF determination. Established RRF values are shown in Table 2. 
 
 
Fig. 5.   Chromatogram and purity plot of base stressed docetaxel injection 
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Precision 
The precision of the method is evaluated by analyzing six samples of test preparation of 
docetaxel injection spiked with Impurities at 0.3% level. The Relative standard deviation is 
found to be less than 5.0% for all the impurities.  
Limit of detection (LOD) and limit of quantification (LOQ) 
The limit of detection, limit of quantification and precision at LOQ values for docetaxel and 
its impurities are shown in Table 2. The precision at LOQ for all the impurities and 
docetaxel is in the RSD range of 1.5-3.7%.The recovery at LOQ level for the impurities is 
in the range of 96.1–108.3%. 
 
Fig. 6.   Overlay of Assay chromatograms of placebo (bottom) and impurities spiked on 
Docetaxel (top) drug product.  
Accuracy 
Recovery study of the impurities are performed at 0.15%, 0.3% and 0.45% levels and 
found that accuracy of the method falls in the range of 90.0% to 110.0%. Accuracy data is 
shown in Table-3. In the new method, care was taken to ensure adequate separation of 
drug related impurities from peaks due to placebo leading to accurate quantification of the 224  A. Malleswara Reddy et al.:  
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impurities. The formulation samples of Docetere
TM (Dr Reddy’s product) and Taxotere® 
(Innovator product) were analyzed. The % of impurities are corrected for their differences 
in responses in chromatography. The results are shown in Table 4  
Linearity 
Linear calibration plot for docetaxel and its impurities is established over the concentration 
range of LOQ to 0.45%. The correlation coefficients are found to be greater than 0.998. 
This shows that an excellent correlation existed between the peak area and the 
concentration of impurities. 
Tab. 1.   Forced degradation study data of Docetaxel formulation for Impurities method. 
 
 
Stress Study  Unstre-
ssed  Oxidation Thermal Base  Acid 
Stress Condition  NA  3% H2O2 
for 12 hrs
100°C 
for 48 
hrs 
2N 
NaOH 
for 1 hr 
2N HCl 
for 24 
hrs 
RRT  K
1 
Name of 
Impurity  % Impurity 
Peak 
Purity 
0.11  4.2  Unknown   ND  1.22  ND  ND  ND  Passes 
0.12  4.6 
10-Deacetyl-
baccatin III  ND  1.63  1.14  9.68  ND  Passes 
0.15  6.0  Unknown   ND  ND  ND  0.3  ND  Passes 
0.17  7.0  Unknown   ND  0.74  0.16  ND  ND  Passes 
0.22  9.3  Unknown   ND  0.48  ND  7.19  ND  Passes 
0.26  11.2  Unknown   ND  ND  0.2  0.96  ND  Passes 
0.70  31.8  Unknown   ND  ND  ND  ND  0.39  Passes 
0.88  40.2  Unknown   0.01  ND  0.12  ND  ND  Passes 
0.91  41.6  Unknown   0.26  0.16  ND  0.15  0.36  Passes 
0.95  43.5  Unknown   0.01  0.04  0.01  0.01  0.04  Passes 
0.97  44.4  Unknown   0.03  0.04  1.26  0.01  ND  Passes 
0.98  44.9  Unknown   ND  0.09  ND  ND  ND  Passes 
1.00  45.8  Docetaxel  99.31  91.39  86.56  43.79  98.81  Passes 
1.05  48.2  10-Oxodocetaxel  0.19  0.18  0.07  0.68  0.2  Passes 
1.10  50.5  7-Epidocetaxel  0.14  4.03  10.22  34.68  0.17  Passes 
1.13  51.9 
10-Oxo 7-epi-
docetaxel  0.04  0.34  0.26  2.52  ND  Passes 
Total degradation  0.69  9.06  13.44  56.21  1.19  NA 
Mass Balance  99.5  97.8  98.5  96.4  99.5  NA 
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Robustness 
In all the deliberately altered chromatographic conditions (flow rate, column temperature 
and composition of organic solvent), all impurities are adequately resolved and elution 
orders remained unchanged. The resolution between critical pair, i.e. 2'-epidocetaxel and 
the oxetane ring opened impurity of Docetaxel is greater than 2.0 and tailing factor for 
docetaxel and its impurities is less than 1.2 in all the conditions.  
Tab. 2.  Relative Retention time (RRT), Limit of Quantification (LOQ), Relative response 
factor (RRF) and Recovery data of the Docetaxel and its Impurities. 
Name of the Impurity  ~RRT  K
1  LOD (in 
%) 
LOQ (in 
%)  RRF % RSD at 
LOQ
a 
%Recovery 
at LOQ
b 
10-Deacetylbaccatin III  0.11  4.2 0.002  0.006  1.53  2.1  99.0 
7-Epi-10-deacetyl- 
baccatin III  0.20 8.3 NA  NA  NA NA  NA 
7-Epi-10-oxo-10-
deacetylbaccatin III  0.22 9.2 NA  NA  NA NA  NA 
2',3'-Epidocetaxel 0.88  39.9 0.003  0.008  0.96 1.9  106.4 
2'-Epidocetaxel 0.94  42.7 0.003  0.009  1.02 3.4  96.4 
Oxetane ring opened 
impurity of Docetaxel  0.97 44.1  0.004  0.011 0.73  2.5  94.7 
Docetaxel 1.00  45.4  0.003 0.008  1.00  1.5  100.6 
10-Oxodocetaxel 1.05  47.8  0.003 0.014  0.91  3.7  108.3 
7'-Epidocetaxel 1.11  50.6 0.003  0.011  1.00 2.4  96.1 
10-Oxo-7'epidocetaxel 1.14  52.0 0.002  0.006  1.35 2.6  97.1 
NE = Not Established due to non-availability of impurity standards; NA= Not applicable; 
a Mean for six 
determinations; 
b Mean for three determinations 
 
Assay 
Assay determinations of injection formulations is best performed by taking total contents of 
the vial and dissolve entire contents into the suitable diluent followed by estimation of the 
total amount of drug present in the solution against the standard. The recent publication 
[12] employs a method wherein a portion of the sample is weighed for sample preparation 
and total drug content present per vial is calculated by weight extrapolation. The method 
involves taking weight of a labeled vial before taking the sample, emptying the contents, 
washing and drying the vial to take the empty weight. This is a not only laborious but also 
can lead to errors of underestimation or overestimation to a significant extent. The present 
study describes a much elegant method which requires only thorough cleaning of the vials 
to ensure transfer of the entire contents into the solution during sample preparation. The 
drug content is estimated using single point external standard calibration using peak area 
calculations. USP tailing factor, theoretical plates and relative standard deviation for 
docetaxel peak is found to be 1.1, 72867, 1.0% respectively.  
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Tab. 3.   Results of recovery study: 
Amount spiked
a %  Recovery
b  Name of the impurity 
50% 100% 150% 50%  100% 150% 
10-Deacetylbaccatin III  0.15 0.3  0.45  99.1  100.2 99.3 
2',3'-Epidocetaxel 0.15 0.3  0.45  100.1 100.5 99.4 
2'-Epidocetaxel 0.15  0.3  0.45 98.2 99.5 98.2 
Oxetane ring opened impurity of Docetaxel  0.15  0.3  0.45 97.8 98.2 97.5 
10-Oxodocetaxel 0.15  0.3  0.45 99.6 99.7 96.7 
7'-Epidocetaxel 0.15  0.3  0.45 96.4 95.7 97.5 
10-Oxo-7'-epidocetaxel 0.15  0.3  0.45 98.9 97.2 96.5 
aAmount of impurities spiked with respect to 0.30% specification level individually to 0.8 mg/ml of 
docetaxel; 
b Mean±%RSD for three determinations. 
 
Tab. 4.   Batch analysis of Impurities for different samples. 
Name of the Product 
Docetere
TM  
80 mg 
Docetere
TM  
20 mg 
Taxotere® 
80 mg 
Batch  No.  A7469 A8252 A7486 A8331 D6D400 
Months before Expiry  9  14  10  16  9 
RRT K
1 Name  %  Impurity 
0.119  4.5  10-Deacetylbaccatin  III  ND ND ND ND ND 
0.200 8.3  7-Epi-10-deacetyl-
baccatin III  ND ND ND ND ND 
0.233 9.8  7-Epi-10-oxo-10-
deacetylbaccatin III  ND ND ND ND ND 
0.425  18.6  Placebo  NA NA NA NA NA 
0.447  19.8  Placebo  NA NA NA NA NA 
0.827  37.4  Placebo  NA NA NA NA NA 
0.872 39.5 Unknown  0.01 0.09 0.04 0.06 0.04 
0.893 40.5 2',3'-Eepidocetaxel ND ND ND ND ND 
0.902 40.9 Unknown  0.09 0.11 0.02 0.04 0.00 
0.945  42.9  2'-Epidocetaxel  ND ND ND ND ND 
0.967 43.9 Unknown  0.03 0.05 0.03 0.01 0.12 
0.972 44.2 Oxetane ring opened 
impurity of Docetaxel  ND ND ND ND ND 
0.98 44.5  Unknown  0.01 0.01 0.01 0.05 0.01 
1.00 45.5  Docetaxel  NA  NA  NA  NA  NA 
1.05 47.8  10-Oxodocetaxel  0.19 0.20 0.22 0.12 0.20 
1.11 50.6  7'-Epidocetaxel 0.11  0.09  0.11 0.13 0.04 
1.14 52.0  10-Oxo-7'-epidocetaxel 0.02 0.03 0.01 0.04 0.00 
Total 
Impurities   0.45  0.45  0.32 0.45 0.41 
NA = Not Applicable; ND = Not Detected 
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The precision of assay method is evaluated by assaying the six individual sample 
preparations. The Mean % assay and Relative standard deviation for % assay was found 
to be 98.7% and 0.64% respectively. Recovery of docetaxel from spiked placebo was 
conducted. Samples were prepared in triplicate by mixing placebo with docetaxel API 
equivalent to about 50%, 100%, and 150% of the assay concentration. The % recovery 
was found to be between 98.0% to 102.0%. A series of solutions of docetaxel standard, 
are prepared in the concentration range of 50%, to 150% of the assay concentration. 
Linearity is established by plotting a graph between concentrations versus peak area. The 
correlation coefficient is found to be of 0.999. This indicates that the assay method is linear 
from 50% to 150% of the target assay concentration 
The method is proved to be stability indicating by establishing the peak purity of Docetaxel 
in the forced degradation samples (Table 5). Different batches of formulation products are 
analyzed and the results are shown in Table 6.The overlay chromatogram of placebo and 
impurities spiked on Docetaxel drug product in assay method is shown in Figure 6. 
Tab. 5.   Forced degradation study data of Docetaxel formulation for assay method. 
Stress Study  Stress condition  Peak purity of Docetaxel 
Unstressed Unstressed  Passes 
Oxidation  3% H2O2 for 12 hours  Passes 
Thermal   100°C for 48 hours  Passes 
Base   2N NaOH for 1 hour  Passes 
Acid   2N HCL for 24 hours  Passes 
 
Tab. 6.   Batch analysis of assay for different samples. 
Docetaxel 
Content 
Docetaxel 
Concentration  Name of the 
Product   Batch No 
Months 
before 
Expiry 
Label claim 
mg/vial mg/ml 
Docetere
TM 20  A7486  10  20 mg / 0.5 ml  23.8  40.3 
Docetere
TM 20  A8331  16  20 mg / 0.5 ml  24.0  40.7 
Docetere
TM 80  A8252  14  80 mg / 2.0 ml  94.5  40.2 
Docetere
TM 80  A7469  9  80 mg / 2.0 ml  95.4  40.6 
Taxotere® 80  D6D400  9  80 mg / 2.0 ml  96.4  40.8 
 
Experimental 
Chemicals, Standards and Impurities 
Acetonitrile (HPLC grade, Merck, India), Methanol (HPLC grade, Merck, India), High pure 
water is from Mill-Q water purification system from Millipore, Acetic acid (AR grade, Merck, 
India).Docetaxel trihydrate Working standard, Impurity standards of 10-DAB-III-2',3'-
Epidocetaxel, 2'-Epidocetaxel, Oxetane ring opened impurity of Docetaxel, 10-
Oxodocetaxel, 7'-Epidocetaxel, 10-Oxo-7-epidocetaxel.  228  A. Malleswara Reddy et al.:  
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Samples 
Taxotere
® 80mg (Docetaxel Injection concentrate from Sanofi Aventis), Docetere
TM 20 mg, 
Docetere
TM 80 mg (Docetaxel Injection concentrate from Dr Reddy’s laboratories limited), 
Different grades of Polysorbate 80 (Vicapol-80 S from Vishwat chemicals, India, Montanox 
80 VGPH from SEPPIC, France, Montanox 80 ESSAI from SEPPIC, France, Montanox 80 
HX from NOF Corporation, Japan, Super refined
® Polysorbate 80 from Croda Inc, USA). 
Equipments 
Agilent 1100 series HPLC system equipped with Quaternery pump with an online 
degasser, auto sampler, thermostatted Column compartment and variable wavelength 
detector. Waters alliance HPLC system equipped with 2695 separations module and 2489 
UV/VIS detector or 2998 Photodiode array detector. Waters Empower1 software is used 
for data acquisition, data processing in HPLC.  
Chromatographic conditions 
A new gradient method is developed for separating process impurities and degradants of 
docetaxel from placebo peaks proving the method to be stability indicating. The 
chromatographic method employs a mobile phase-A consisting of a mixture of water, 
acetonitrile & methanol in the ratio of 50:20:30(v/v) and a mobile phase-B consisting of a 
mixture of water & acetonitrile in the ratio of 20:80(v/v). The method employs a gradient 
program listed in Table-7 for impurities analysis and Table 8 for assay analysis using 150 
mm x 4.6 mm,  YMC Pack ODS-A, 3 µm column maintained at ambient temperature 
(25±2°C) and the detector set at wavelength of 230 nm. An Injection volume of 25µL is 
used for impurities analysis and 5µL is used for assay analysis. 
Tab. 7.   HPLC Gradient program for impurities analysis. 
Time (min)  Flow rate 
(ml/min)  % Mobile Phase A  % Mobile Phase B Gradient Curve 
0–25 1.0 100  0  Isocratic 
25–60 1.0  100→20 0→80 Linear 
60–65 1.0  20→100 80→20 Linear 
65–75 1.0  100  0  Equilibration 
 
Tab. 8.  HPLC Gradient Program for assay analysis. 
Time (min)  Flow rate 
(ml/min)  % Mobile Phase A  % Mobile Phase B  Gradient Curve 
0–25 1.0 95→40 5→60 Linear 
25–26 1.0  40→95 60→5 Linear 
26–35 1.0  95  5  Equilibration   
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Sample preparations for Assay and Impurities 
Contents of the drug product vial is dissolved in 4 ml of diluent (water:acetonitrile: 50:50, 
v/v) and transferred into a suitable volumetric flask. Each vial is again washed thoroughly 
with small portions of diluents to remove the drug product completely into the volumetric 
flask. Then the solution is made up to the volume with diluent and mixed well. 
For 20 mg docetaxel injection, total contents of one vial is dissolved and diluted to 25 ml. 
For 80 mg docetaxel injection, total contents of one vial is dissolved and diluted to 100 ml. 
This results in a sample solution of 0.8 mg of docetaxel per ml. A placebo (formulation 
matrix without drug) sample solution is prepared in similar manner for Docetere 
formulation. Sample solutions of different grades polysorbate 80 are prepared using 
equivalent weights into the similar volumes. An accurately weighed amount of docetaxel 
trihydrate is dissolved in diluent to obtain a standard solution having a known 
concentration of 0.8 mg/ml. 
Specificity and mass balance study 
Specificity is the ability of the method to measure the analyte response in the presence of 
its potential impurities and degradation products [13]. The specificity of the developed LC 
method for docetaxel was carried out in the presence of its impurities. Sample is subjected 
to acid hydrolysis, alkaline hydrolysis and oxidation conditions. Sample is also subjected to 
thermal and photo degradation in dry state. Different stress conditions are followed to 
achieve degradation. The degraded samples are diluted to get 0.8mg/ml of docetaxel. The 
total impurities and assay are estimated with respective methods. 
Limit of detection (LOD) and limit of quantification (LOQ) 
The LOD and LOQ for impurities and docetaxel are estimated at a signal-to-noise ratio of 
3:1 and 10:1, respectively by injecting a series of diluted solutions with known 
concentration. Precision study was also carried at the LOQ level by injecting six individual 
preparations of all impurities and docetaxel and calculating the % RSD. Accuracy at LOQ 
level is evaluated in triplicate for the impurities by spiking the impurities at the estimated 
LOQ level to test solution. 
Precision 
Precision of assay method is evaluated by carrying out six independent assays of test 
sample of docetaxel drug product against qualified docetaxel standard and calculated the 
% RSD. The precision of the impurities method is verified by injecting six individual 
preparations. Docetaxel drug product spiked with 0.3% of known impurities with respect to 
docetaxel concentration. % RSD for each known impurity is calculated.  
Accuracy 
The accuracy of the assay method is evaluated in triplicate at three concentration levels, 
i.e. 50, 100 and 150% of the assay concentration. The %recovery is calculated against 
0.8mg/ml of standard preparation. Recovery experiments were conducted to determine 
accuracy of impurities method for the quantification of all impurities in drug product. The 
study was carried out in triplicate at 0.15%, 0.3% and 0.45% of the test concentration. 
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Linearity 
Linearity test solutions for the assay method are prepared from docetaxel stock solutions 
at five concentration levels from 50 to 150% of assay analyte concentration (50, 75, 100, 
125 and 150%). The peak area versus concentration data is treated by least-squares 
linear regression analysis. Linearity solutions for the impurities method were prepared by 
diluting impurity stock solutions to the required concentrations. The solutions are prepared 
at different concentration levels from LOQ to 0.45%. 
Robustness 
To determine the robustness of the developed method, experimental conditions are 
deliberately altered and the resolution between docetaxel and its impurities and tailing 
factor for docetaxel and its impurities are recorded. The effect of flow rate is studied at 
0.8ml/min and 1.2ml/min and compared with method flow rate of 1.0ml/min. The effect of 
column temperature is studied at 20°C and 30°C and compared with method column 
temperature 25°C. The effect of composition of organic solvents is studied by varying 
acetonitrile and methanol individually by −5 to +5% while other mobile phase components 
are held constant and compared with method organic solvent composition. 
Conclusion 
The present study emerged with suitable impurities and assay methods for evaluation of 
pharmaceutical quality of docetaxel in docetaxel injection formulations. The impurities 
method is designed by taking adequate care to separate process related impurities, 
degradation products, placebo components from each other and also from docetaxel. The 
method also identifies the retention times of known impurities and ensures their 
quantification accurately employing relative response factors. A simpler and accurate 
assay method for determination of drug content in docetaxel formulation is established. 
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